Geoff Houlton
Senior Healthcare Analyst. at Union Securities
Member since: Mar '08 · 7 Opinions
Rating
Big Win
Win
Neutral
Loss
Big Loss
Stock Opinions by Geoff Houlton
TRADE
A drug that corrects complications that occur with the prostrate and prostrate cancer. Entering phase 2 clinical trials, has large market opportunities. Have done safety studies. In good shape regarding their cash position.
Consumer Products
BUY
Has raised capital. Produces a hand held company to assist primary care physicians, to help electronic prescribing. It doesn’t cost the physician anything. The company is doing very well.
electrical
electronic
BUY
Has done tremendously well. They focus on wound care products, and coatings for products. The company has tremendous potential, they signed a deal with a large British company. Great opportunity, going to do well going forward.
medical services
BUY
A very interesting company. Has an animal health product, human health products focused on bladder cancer and a vaccine for cattle. Likes the company, has existing products (short-term revenue stream) and has future opportunity and a potential blockbuster product. A significant opportunity.
biotechnology
pharmaceutical
WEAK BUY
Been around for a long time. Has a broad range of technologies. Have recently signed licensed for Virusmax, which can double the yield of virus production for vaccinations. Bull semen-sexing technology. Have some very interesting technologies. Watching it very closely. Like the company.
biotechnology
pharmaceutical
TOP PICK
Focuses on providing software for doctors, directed at Primary physicians. Have lots of new products coming through. Great opportunity.
computer software
processing
TOP PICK
Recently suffered when phase 3 testing failed. Has cash in the bank, has a long runway (cash on a burn rate). Have 2 products in phase 3, one of which is approved in India and China. Great opportunities. Way undervalued.
biotechnology
pharmaceutical
Showing 1 to 7
of 7 entries
- «
- ‹
- 1
- ›
- »
Advertising